Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Sequenom’s Down syndrome test

You may also be interested in...

New Products In Brief

A drug-eluting stent and prostate cancer assay are among newly approved devices.

News In Brief

InSightec submits ExAblate PMA to treat pain caused by bone metastases. AngioDynamics initiates NanoKnife software recall. Sequenom raises $62 million in secondary stock offering. More news briefs.

Segasist Awaits 510(k) Clearance For "Self-Training" Auto-Contouring Tool

Segasist expects FDA to decide as early as this month on a 510(k) submission for a prostate-contouring software system designed to "learn" as it goes and become more and more accurate the more it is used.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts